Git Pathogenic Bacteria
-
Upload
annisaa-fitriani -
Category
Documents
-
view
242 -
download
0
Transcript of Git Pathogenic Bacteria
-
7/29/2019 Git Pathogenic Bacteria
1/12
Food borne Pathogenic Bacteria
Riyani Wikaningrum
Bag. MikrobiologiFK Universitas YARSI
-
7/29/2019 Git Pathogenic Bacteria
2/12
The GIT defense
mechanisms
-
7/29/2019 Git Pathogenic Bacteria
3/12
Terminologies Gastroenteritis
A syndrome characterized by gastrointestinal symptoms including
nausea, vomiting, diarrhea and abdominal discomfort
Diarrhea
Abnormal fecal discharge characterized by frequent and/or fluid stool;
usually resulting from disease of the small intestine and involvingincreased fluid and electrolyte loss
Dysentery
An inflammatory disorder of the gastrointestinal tract often associated
with blood and pus in the feces and accompanied by symptoms of
pain, fever, abdominal cramps; usually resulting from disease of thelarge intestine
Enterocolitis
Inflammation involving the mucosa of both the small and large
intestine
-
7/29/2019 Git Pathogenic Bacteria
4/12
Results of GIT Infections
Pharmacologic action of bacterial toxins, local or
distant to site of infection
e.g. cholera, staphylococcal food poisoning
Local inflammation in response to superficial
microbial invasion e.g. shigellosis, amebiasis
Deep invasion to blood or lymphatics; dissemination
to other body sites
e.g. Hepatitis A, enteric fevers
Perforation of mucosal epithelium after infection,
surgery or accidental trauma
e.g. peritonitis, intra-abdominal abscesses
-
7/29/2019 Git Pathogenic Bacteria
5/12
Pathogenic Bacteria
Salmonella spp.
Clostridium botulinum
Staphylococcus aureus
Campylobacter jejuni
Yersinia enterocolitica Yersinia pseudotuberculosis
Listeria monocytogenes
Vibrio cholerae O1
Vibrio cholerae non-O1 Vibrio parahaemolyticus
and other vibrios
Vibrio vulificus
Clostridium perfringens
Bacillus cereus
Aeromonas hydrophila andother spp.
Plesiomonas shigelloides
Shigella sp.
Miscellaneous enterics
Streptococcus
Clostridium difficile
http://www.cfsan.fda.gov/~mow/chap1.htmlhttp://www.cfsan.fda.gov/~mow/chap2.htmlhttp://www.cfsan.fda.gov/~mow/chap3.htmlhttp://www.cfsan.fda.gov/~mow/chap4.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap6.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap10.htmlhttp://www.cfsan.fda.gov/~mow/chap11.htmlhttp://www.cfsan.fda.gov/~mow/chap12.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap18.htmlhttp://www.cfsan.fda.gov/~mow/chap19.htmlhttp://www.cfsan.fda.gov/~mow/chap19.htmlhttp://www.cfsan.fda.gov/~mow/chap20.htmlhttp://www.cfsan.fda.gov/~mow/chap21.htmlhttp://www.cfsan.fda.gov/~mow/chap21.htmlhttp://www.cfsan.fda.gov/~mow/chap20.htmlhttp://www.cfsan.fda.gov/~mow/chap20.htmlhttp://www.cfsan.fda.gov/~mow/chap19.htmlhttp://www.cfsan.fda.gov/~mow/chap19.htmlhttp://www.cfsan.fda.gov/~mow/chap19.htmlhttp://www.cfsan.fda.gov/~mow/chap18.htmlhttp://www.cfsan.fda.gov/~mow/chap18.htmlhttp://www.cfsan.fda.gov/~mow/chap18.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap17.htmlhttp://www.cfsan.fda.gov/~mow/chap12.htmlhttp://www.cfsan.fda.gov/~mow/chap11.htmlhttp://www.cfsan.fda.gov/~mow/chap11.htmlhttp://www.cfsan.fda.gov/~mow/chap10.htmlhttp://www.cfsan.fda.gov/~mow/chap10.htmlhttp://www.cfsan.fda.gov/~mow/chap10.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap9.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap8.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap7.htmlhttp://www.cfsan.fda.gov/~mow/chap6.htmlhttp://www.cfsan.fda.gov/~mow/chap6.htmlhttp://www.cfsan.fda.gov/~mow/chap6.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap5.htmlhttp://www.cfsan.fda.gov/~mow/chap4.htmlhttp://www.cfsan.fda.gov/~mow/chap4.htmlhttp://www.cfsan.fda.gov/~mow/chap3.htmlhttp://www.cfsan.fda.gov/~mow/chap3.htmlhttp://www.cfsan.fda.gov/~mow/chap2.htmlhttp://www.cfsan.fda.gov/~mow/chap2.htmlhttp://www.cfsan.fda.gov/~mow/chap1.html -
7/29/2019 Git Pathogenic Bacteria
6/12
GIT
Infections
-
7/29/2019 Git Pathogenic Bacteria
7/12
Clostridium difficile
-
7/29/2019 Git Pathogenic Bacteria
8/12
Clostridium difficile
Dapat ditemukan sebagai flora normal usus
Penyebab pseudomembraneus colitis, diare
akibat pemakaian antibiotik (AAD)
Menghasilkan:
toxin yang bersifat sitopatik
Enterotoxin
Diagnosis berdasarkan ditemukannya
cytotoxin dalam feses.
-
7/29/2019 Git Pathogenic Bacteria
9/12
C. d iff ic i le
o After antibiotic use
o Intestinal normal flora
greatly decreased
o Colonization occurs
o Enterotoxin secretedo Pseudomembanous
colitis
-
7/29/2019 Git Pathogenic Bacteria
10/12
Antibiotic-associated colitis due to Clostridium difficile. Sigmoidoscopic view
showing multiple pseudomembranous lesions
-
7/29/2019 Git Pathogenic Bacteria
11/12
Pseudomembranous Coli t is
Pseudomembranous colitis (PC) results
predominantly as a consequence of the
elimination of normal intestinal flora through
antibiotic therapy. Symptoms:
include abdominal pain
watery diarrhea and leukocytosis
"Pseudomembranes" consisting of fibrin, mucus andleukocytes endoscopy
Untreated pseudomembranous colitis fatal in
about 27-44%.
-
7/29/2019 Git Pathogenic Bacteria
12/12
Therapy
Discontinuation of initial antibiotic
(e.g. ampicillin)
Specific antibiotic therapy (e.g.
vancomycin)